| 000 | 01622 a2200493 4500 | ||
|---|---|---|---|
| 005 | 20250512233316.0 | ||
| 264 | 0 | _c19820624 | |
| 008 | 198206s 0 0 eng d | ||
| 022 | _a0028-3878 | ||
| 024 | 7 |
_a10.1212/wnl.32.5.503 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aKaroum, F | |
| 245 | 0 | 0 |
_aMetabolism of (-) deprenyl to amphetamine and methamphetamine may be responsible for deprenyl's therapeutic benefit: a biochemical assessment. _h[electronic resource] |
| 260 |
_bNeurology _cMay 1982 |
||
| 300 |
_a503-9 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article | ||
| 650 | 0 | 4 |
_a3,4-Dihydroxyphenylacetic Acid _xmetabolism |
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 |
_aAmphetamines _xmetabolism |
| 650 | 0 | 4 |
_aBiogenic Amines _xmetabolism |
| 650 | 0 | 4 |
_aCarbidopa _xtherapeutic use |
| 650 | 0 | 4 |
_aDepression _xmetabolism |
| 650 | 0 | 4 |
_aDrug Combinations _xtherapeutic use |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aLevodopa _xtherapeutic use |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 |
_aMethamphetamine _xmetabolism |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 |
_aMonoamine Oxidase _xmetabolism |
| 650 | 0 | 4 |
_aParkinson Disease _xdrug therapy |
| 650 | 0 | 4 |
_aPhenethylamines _xmetabolism |
| 650 | 0 | 4 |
_aSelegiline _xmetabolism |
| 650 | 0 | 4 |
_aTyramine _xmetabolism |
| 700 | 1 | _aChuang, L W | |
| 700 | 1 | _aEisler, T | |
| 700 | 1 | _aCalne, D B | |
| 700 | 1 | _aLiebowitz, M R | |
| 700 | 1 | _aQuitkin, F M | |
| 700 | 1 | _aKlein, D F | |
| 700 | 1 | _aWyatt, R J | |
| 773 | 0 |
_tNeurology _gvol. 32 _gno. 5 _gp. 503-9 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1212/wnl.32.5.503 _zAvailable from publisher's website |
| 999 |
_c6802938 _d6802938 |
||